Latrunculin A
Based on 12 publication(s) in Google Scholar
Latrunculin A (LAT-A), found in the red sea sponge Latrunculia magnifica, is a G-actin polymerization inhibitor. Latrunculin A binds to actin monomers and inhibits polymerization of actin with Kds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively. Latrunculin A has effective anti-metastatic properties for cancer research. Latrunculin A blocks cell migration.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.9%
- CAS No.: 76343-93-6
- Formule: C22H31NO5S
- Masse moléculaire:421.55
-
Stockage:
Solution, -20°C, 2 years
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Latrunculin A
More- Nat Commun. 2022 Sep 26;13(1):5657. [Abstract]
- J Extracell Vesicles. 2022 May;11(5):e12218. [Abstract]
- Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
- Carbon. 2025 Dec 22;248:121179.
- Apoptosis. 2023 Aug;28(7-8):1048-1059. [Abstract]
- Ecotoxicol Environ Saf. 2024 Dec 24:290:117598. [Abstract]
- Talanta. 2024 Feb 1;268(Pt 1):125286. [Abstract]
- PLoS Pathog. 2026 Feb 27;22(2):e1014000. [Abstract]
- mBio. 2025 Oct 8;16(10):e0194525. [Abstract]
- Exp Cell Res. 2025 Feb 21;446(1):114461. [Abstract]
- New J Chem. 2023 Jun 28.
- bioRxiv. 2023 Feb 5.
Customer Validation & Images
-
Flow Cytometry
-
ELISA
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
Flow Cytometry
Activité biologique
Kd: 0.1 μM (ATP-actin), 0.4 μM (ADP-Pi-actin), 4.7 μM (ADP-actin), 0.19 μM (G-actin)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.06 μg/mL
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 8350092] |
| HCT-116 | IC50 |
1.1 μM
Compound: 1, NSC-613011
|
Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay
Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay
|
[PMID: 18942825] |
| HT-29 | IC50 |
0.06 μg/mL
Compound: 1
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 8350092] |
| HT-29 | IC50 |
0.08 μg/mL
Compound: 10
|
Antiproliferative activity against human HT-29 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay
Antiproliferative activity against human HT-29 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay
|
[PMID: 22129061] |
| MCF7 | IC50 |
0.48 μM
Compound: 99a
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33940466] |
| MDA-MB-231 | IC50 |
4.19 μM
Compound: 99a
|
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33940466] |
| MDA-MB-435 | IC50 |
0.04 μg/mL
Compound: 10
|
Antiproliferative activity against human MDA-MB-435 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay
Antiproliferative activity against human MDA-MB-435 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay
|
[PMID: 22129061] |
| MDA-MB-435 | IC50 |
2.8 μM
Compound: 1, NSC-613011
|
Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay
|
[PMID: 18942825] |
| P388 | IC50 |
4.1 μg/mL
Compound: 1
|
Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay
|
[PMID: 8350092] |
| P388 | IC50 |
4.1 μg/mL
Compound: Latrunculin A
|
Antiproliferative activity against mouse P388 cells
Antiproliferative activity against mouse P388 cells
|
10.1021/np50082a019 |
| T47D | IC50 |
25 μM
Compound: 1,Latrunculin A
|
Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells by cell based reporter gene assay
Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells by cell based reporter gene assay
|
[PMID: 18298079] |
| T47D | IC50 |
6.7 μM
Compound: 1,Latrunculin A
|
Inhibition of hypoxia-induced HIF1 activation in human T47D cells by cell based reporter gene assay
Inhibition of hypoxia-induced HIF1 activation in human T47D cells by cell based reporter gene assay
|
[PMID: 18298079] |
| U-937 | IC50 |
0.07 μg/mL
Compound: 10
|
Antiproliferative activity against human U937 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay
Antiproliferative activity against human U937 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay
|
[PMID: 22129061] |
Latrunculin A (50-1000 nM) exhibits potent anti-invasive activity against human prostate cancer PC-3M cells, inhibits PC-3M-CT+ spheroids disaggregation and cell migration[3].
?
Latrunculin A (3-30 μM) inhibits hypoxia-induced HIF-1 activation with an IC50 value of 6.7 μM in human breast carcinoma T47D cells[3].
?
Latrunculin A (0-0.2 μM, 4 hours) has a significant inhibitory effect on HuR levels at high concentrations such as 0.2 μM in human hepatoma HepG2 cells while inhibits HuR only at 0.02 μM but no inhibitory effect at high concentrations in human hepatoma Huh7 cells[4].
?
Latrunculin A (0.1 μM, 24 hours) can lead to a significant decrease in cell migration and has an inhibitory effect on cell proliferation in human hepatoma cell lines HepG2[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4)[5]
-
Dosage:0.05 mg/kg
-
Administration:Intraperitoneal injection; three doses in the first 20 days; 120 days
-
Result:Extended the mean life expectancy to 23.5 days comparing to control of 16 days in adenocarcinoma (MKN45) mice and the mean survival time was 42 days comparing to untreated of 31 days in carcinoma (NUGC-4) mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 76343-93-6
-
Appearance Liquid
-
Masse moléculaire 421.55
-
Formule C22H31NO5S
-
Color Colorless to light yellow
-
SMILES
O=C1SC[C@@H]([C@]2(O)O[C@]3([H])CC[C@H](C)/C=C\C=C\CC/C(C)=C\C(O[C@@](C3)([H])C2)=O)N1
-
Synonyms
LAT-A
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Solution, -20°C, 2 years
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells. [Abstract]2022 Sep 26;13(1):5657. PMID: 36163326 -
J Extracell Vesicles
CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. [Abstract]2022 May;11(5):e12218. PMID: 35524455 -
Adv Sci (Weinh)
Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RARγ-Translocation-Mediated Tension Reduction and Chromatin Decondensation. [Abstract]2022 Aug 28;e2203173. PMID: 36031407
Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
The sEVs (50 μg) were cocultured with macrophages (1 × 106) for 24 h. The sEVsHNSCC derived from two HNSCC lines: SCC25 and HN6. The sEVshBMSC-NT5EOE derived from hBMSC cells with NT5E overexpression. Latrunculin A (Lat A, 30 μM; 24 h) was used as the inhibitor of sEVs uptaken showed downregulated phagocytosis. The percentage of pHrodo dyes of M2 macrophages was analyzed by flow cytometry.
Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
The expression of cytokines also increased when macrophages were cocultured with sEVs derived from hBMSCs overexpressing CD73, whereas this trend was reversed by Latrunculin A (Lat A, 30 μM; 24 h).
Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
Macrophages were cocultured with anti-CD73-FITC labelled sEVs from HNSCC cell lines control or RABAKO, CD73-GFP labelled sEVs from hBMSC treated with or without Latrunculin A (Lat A, 30 μM; 24 h) were cocultured with macrophages for 1 h, and Laser Scanning Confocal Microscopy was used to analyze the internalization of HNSCC-derived sEVs into macrophages (Scale bar = 25 μm).
Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
Absence of CD73 in sEVs rescues immune suppression and restrains tumour growth in C3H/He mice aged 6–8 weeks. (a) Schematic of subcutaneous tumorigenesis in vivo experiment, followed with intratumoral injection of sEVs which were collected from SCC7, SCC7-Nt5eKO or SCC7-Nt5eOE cells grown in vitro. (b) The exhibition of isolated tumours. (c and d) The tumour weight and the time course of tumour growth in grams for 15 days postinjection with SCC7 or SCC7Rab27aKO cells with or without CD73 in sEVs. Latrunculin A (Lat A, 0.15 mg/kg; ip; every 2 days for 15 days) was used as inhibitor of sEVs uptaken.
Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
Latrunculin A (Lat A, 0.15 mg/kg; ip; every 2 days for 15 days) was used as an inhibitor of sEVs uptake in C3H/He mice aged 6–8 weeks. Flow cytometry analysis for infiltration of Tregs and percentage of CD73+/PD-1+ Tregs in tumours.
-
-
Apoptosis
TFAM-Mediated mitochondrial transfer of MSCs improved the permeability barrier in sepsis-associated acute lung injury. [Abstract]2023 Aug;28(7-8):1048-1059. PMID: 37060506 -
Ecotoxicol Environ Saf
Lead-induced actin polymerization aggravates neutrophil extracellular trap formation and contributes to vascular inflammation. [Abstract]2024 Dec 24:290:117598. PMID: 39721424 -
Talanta
Super-resolution imaging of folate receptor alpha on cell membranes using peptide-based probes. [Abstract]2024 Feb 1;268(Pt 1):125286. PMID: 37832456 -
PLoS Pathog
2026 Feb 27;22(2):e1014000. PMID: 41758870 -
mBio
PRRSV promotes bacterial infection by remodeling actin cytoskeleton and cell membrane proteins. [Abstract]2025 Oct 8;16(10):e0194525. PMID: 40937850 -
Exp Cell Res
Mechanical stretch promotes the migration of mesenchymal stem cells via Piezo1/F-actin/YAP axis. [Abstract]2025 Feb 21;446(1):114461. PMID: 39988125 -
-
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Fujiwara I, et al. Latrunculin A Accelerates Actin Filament Depolymerization in Addition to Sequestering Actin Monomers. Curr Biol. 2018 Oct 8;28(19):3183-3192.e2. [Content Brief]
[2]. Coué M, et al. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 1987 Mar 23;213(2):316-8. [Content Brief]
[3]. Khalid A El Sayed, et al. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod. 2008 Mar;71(3):396-402. [Content Brief]
[4]. Anke Doller, et al. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res. 2015 Jan 1;330(1):66-80. [Content Brief]
[5]. Hiroo Konishi, et al. Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res. 2009 Jun;29(6):2091-7. [Content Brief]
[6]. Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz